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Satiety Effects of the Type A CCK Receptor Antagonist 
Loxiglumide in Lean and Obese Women
Rob J. Lieverse, Ad A.M. Masclee, Jan B.M J. Jansen,
■
Lucio C. Rovati, and Comelis B.H.W. Lamers
Several studies have demonstrated that administration of cholecystokinin ( CCK) reduces food 
intake in several species, including humans. In animal studies CCK-receptor antagonists have 
been reported to increase food intake, suggesting a physiological satiety effect of CCK in these 
animals. In a double-blind, placebo-controlled study, we investigated the effect of the specific 
CCK-A receptor antagonist loxiglumide on food intake (carbohydrate-rich meal) and on 
subjective hunger feelings scored with visual analogue scales and food selection lists in seven 
healthy obese women and in seven healthy lean women. Loxiglumide was administered intrave­
nously in a dose o f 10 mg/kg ideal weight/h. For the whole group, food intake during loxiglu­
mide (359 ±  39 g ) was not significantly different from food intake during saline infusion (333 ±
31 g). Also, when the lean and obese subgroups were analyzed separately, no significant 
influence of loxiglumide on food intake was found. In addition, no significant differences in 
satiety scores were seen using the food selection lists or visual analogue scales. In conclusion, 
in the present study during infusing the CCK-A receptor antagonist loxiglumide we found no 
increase in preprandial satiety nor in food intake of a carbohydrate-rich meal nor in postpran­
dial satiety in lean and obese women.
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food intake
Introduction
Cholecystokinin (CCK) was identified from preparations of 
intestinal extracts by its ability to stimulate gallbladder con­
traction (Liddle 1989). Several other biological actions of 
CCK have subsequently been identified, like stimulation of 
pancreatic exocrine enzyme secretion, inhibition of gastric 
emptying, influences on intestinal motility, and effects on
From the Department of Gastroenterology and Hepatology, University Hospitals of 
Leiden and Nijmegen, the Netherlands (RJL, AAMM, JBMJJt CBHWL), and 
Rotta Laboratories, Monza Italy (LCR).
Address reprint requests to A.A.M, Masclee, Dept, Gastroenterology and Hepato- 
logy, University Hospital, Building 1, C4-Pt Rijnsburgerweg 10,2333 AA LEI­
DEN, The Netherlands; Fax: ++3 Î-71248115,
Received December 14,1993; revised April 29,1994.
food intake (Liddle 1989). Several studies have demon­
strated that CCK reduces food intake in several species 
including humans (Linden 1989; Gibbs et al 1973; Bado et 
al 1988; Gregory et al 1989; Weller et al 1989; Stacher 
1986; Pi-Sunyer et al 1982; Kissileff et al 1981 ; Stacher et al 
1982). It is, however, not known whether this satiety effect 
of CCK is physiological in humans, since plasma CCK 
levels have not been measured. It is quite possible that in the 
human studies in which a satiety effect of CCK was demon­
strated, plasma CCK levels were in the supraphysiological 
range. However, in a number of animal species it has been 
shown that administration of a CCK-A receptor antagonist 
increases food intake (Silver et al 1989; Reidelberger et al
© 1995 Society of Biological Psychiatry 0006-3223/95/509.50 
SSDÌ 0006-3223(94)00136-Q
332 BIOL PSYCHIATRY
1995;37:331-335
R.J. Lieverse et al
1989; Ebenezer et al 1990; Hewson et al 1900; Smith et al
1991 ; Corwin et al 1991 ). We have investigated whether the 
potent and specific CCK-A receptor antagonist loxiglumide 
(CR1505) (Makovec et al 1985) increases food intake in 
lean and obese healthy women. If so, this would be an 
important indication for a physiological satiety effect of
CCK in humans.
Materials and Methods
Seven healthy obese women (mean age 43 ±  3 yr, mean 
body mass index 39 ±  2 kg/m2) and seven healthy lean 
women (mean age 42 ±  3 yr, mean body mass index 22 ±  
0.3 kg/m2) were studied. Informed consent was obtained 
from all subjects. The protocol had been approved by the 
local human ethics committee.
After an overnight fast, the volunteers presented at our 
laboratory at 08.00 h. An intravenous cannula was inserted 
into the antecubital vein of one arm for infusion of loxiglu­
mide or saline (placebo). Saline or loxiglumide 10 mg/kg 
ideal weight/h (Rotta Research Laboratories, Monza, Italy) 
was infused through an intravenous catheter for 165 min, in 
random order and double blinded. In obese persons the ideal 
weight was calculated by subtracting 100 from their body 
length in cm (Broca weight) (Kelke et al 1992), while for 
lean subjects their actual weight was used. We have shown 
in previous investigations that this calculation used for the 
infusion of gastrointestinal hormones such as CCK results 
in comparable plasma hormone levels between lean and 
obese subjects (Lieverse et al 1993). The infusions were 
started at 09.00 h. The two studies were separated from each 
other by an interval of at least 1 week. The investigations 
were performed irrespective of the time of the menstrual 
cycle. Sixty minutes after the start of the saline or loxiglu­
mide infusion, a banana shake consisting of 100 g of bana­
nas (132 kcal), supplemented with water to 300 ml and 
blended, was served and consumed within 3 minutes. Fif­
teen minutes later, at time 75 min, a solid meal of banana 
slices containing 1 g/100 g of protein, 0 g/100 g of fat, and
32 g/100 g of carbohydrates was offered in abundance. The 
meal was weighed before and after consumption to deter­
mine the exact amount of food consumed.
Subjective criteria like the wish to eat, hunger feeling, 
fullness, and prospective feeding intentions were scored on 
100-mm visual analogue scales (Blundell and Burley 1987; 
Silverstone 1982). These criteria were assessed basally and 
at 15 -min interval until 60 min after the end of the infusion 
period. The following questions were asked:
How strong is your wish to eat? (from very weak to very 
strong).
How hungry do you feel? (from not hungry at all to as 
hungry as I have ever felt).
How full do you feel? (from not full at all to very full).
How much food do you think you could eat? (from nothing
to very much).
In addition, the subjects also indicated on visual analogue 
scales whether they appreciated the meal and whether they 
experienced nausea. Subjective hunger feelings were also 
measured with food selection lists, as described by Hill 
(1987) and modified for Dutch feeding customs. Each food 
selection list was accompanied by a photograph showing 6 
protein-rich, 6 fat-rich, 6 carbohydrate-rich (each about 200 
kcal) and 6 low-energy items. For each of these 24 items, the 
subjects were asked if they wanted to eat the item at that 
moment and to indicate the amount, double the amount, half 
the amount, or nothing of the item they wished to consume. 
Every item was scored independent of the other items. Sub­
jects were presented with a food-selection list 15 min before 
the infusion, 15 min before the banana shake (at time 45 
min), 15 min after the meal (at time 90 min), and at time 120 
min, time 165 min (end of the infusion), and time 225 min 
(end of the experiment). Every time the list was presented, 
the total amount of caloric items was calculated (half the 
amount = 1/2 caloric item, double the amount = 2 caloric 
items).
Statistical Analysis
Results are given as mean ±  SEM. Statistical analysis of 
hunger feelings was performed by calculating the incre­
mental integrated area under the curve (AUC) before and 
after the meal, followed by Wilcoxon matched pairs signed 
rank test. Food intake was compared using Wilcoxon 
matched pairs signed rank test. Differences between lean 
and obese subjects were analyzed using Mann-Whitney test. 
The significance level was set atp <  .05.
Results
For the whole group (obese and lean women together) food 
intake was not significantly different between the loxiglu­
mide experiment (359±39 g) and the control experiment 
(333 ±  31 g). Neither was food intake significantly different 
between the loxiglumide and control experiment in the lean 
subjects (405 ±  56 g vs. 365 ±  42 g, respectively) nor in the 
obese subjects (313 ±  54 g vs. 301 ±  45 g, respectively; 
Figure 1). No significant differences were seen between 
loxiglumide and saline infusion using the food selection 
lists or the visual analogue scales (Table 1, Figure 2). Look­
ing at lean and obese subjects separately, there was a de­
crease in prospective feeding intentions in the lean group 
during loxiglumide (p = .028, Table 1). There was a signifi­
cant greater postprandial satiety effect (p <  .01) during 
loxiglumide in the obese than in the lean individuals for 
wish to eat (p = .006), hunger feelings (p = .009), and 
fullness (p = .003) (Table 1). No other significant differ­
ences between loxiglumide and saline or between obese and 
lean subjects were found (Table 1).
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ate as long during loxiglumide (6.4 ±  0.8 min) as during 
saline (6.1 ± 0.6 min). No nausea during any study was 
recorded in lean or obese subjects.
Discussion
In contrast to studies in several animal species, we did not 
observe a significant increase in food intake during admin­
istration of the potent and specific CCK-A receptor antago­
nist loxiglumide in humans. Neither in the obese nor in the 
lean women was there a significant difference in food intake 
between the loxiglumide and the control experiment. In 
addition, we found no increase in preprandial or postpran­
dial subjective hunger feelings during loxiglumide admin­
istration compared to placebo.
Recently, Wolkowitz et al observed in eight healthy male 
volunteers a significant increase in hunger feelings with 
MK-329, another CCK-A antagonist (Wolkowitz et al 
1990), whereas we found no significant increase in hunger 
sensations. The cause of this difference is not apparent, but 
it may be related to differences in study protocols. First, in 
the study of Wolkowitz et al the CCK-A receptor antagonist 
was administered orally, whereas in our study the CCK-A
Table 1. Incremental Areas under the Curve (mean ±  SEM) for Different Satiety Parameters 
Preprandially (during 60 min) and Postprandially (during 135 min) with Saline or 
Loxiglumide ( 10 mg/kg ideal weight/h) Infusion
All 
(n = 14)
Lean
(n = 7)
Obese 
(« = 7)
p  (lean 
vs. obese)
Wish to eat
preprandial saline 133 ±118 182 ± 2 1 7 84 ±  112 NS*
preprandial loxiglumide 245 ± 188 247 ± 3 6 3 242 ±  148 NS
p  (saline vs. loxiglumide) NS NS NS
postprandial saline 1402 ± 363 1659 ±  400 1145 ±  624 NS
postprandial loxiglumide 962 ± 489 1988 ±  619 -63  ±  551 0.006
p  (saline vs. loxiglumide) NS NS NS
Hunger
preprandial saline 160 ± 130 197 ±  197 122± 186 NS
preprandial loxiglumide 103 ± 172 -103 ± 2 9 5 309 ± 165 NS
p  (saline vs. loxiglumide) NS NS 0.091
postprandial saline 1355 ± 307 1831 ± 433 879 ±371 0.084
postprandial loxiglumide 850 ±419 1768 ±  455 -69  ±  523 0.009
p  (saline vs. loxiglumide) NS NS NS
Fullness
preprandial saline - 9 2 ± 117 -2 2 0  ±  189 35 ±  134 NS
preprandial loxiglumide —80 ± 114 -135  ± 2 1 9 -25 ±  85 NS
p  (saline vs. loxiglumide) NS NS NS
postprandial saline -1452 ± 497 -1737 ±  962 -1169 ± 3 4 6 NS
postprandial loxiglumide -1 1 0 9 1 5 3 7 -2464 ±  566 246 ± 5 6 4 0.003
p  (saline vs. loxiglumide) NS NS NS
Prospective feeding
preprandial saline 277 ± 156 496 ±  282 59 ±  100 NS
preprandial loxiglumide -100 ± 97 -271 ± 108 70 ±  140 0.064
p  (saline vs. loxiglumide) NS 0.028 NS
postprandial saline 1381 ±382 1459 ±  570 1302 ±  552 NS
postprandial loxiglumide 1122 ±361 1697 ±  607 546 ±  291 0.084
p  (saline vs. loxiglumide) NS NS 0.091
values >  0.10 are given as NS.
500
9
400
300
200
100
0
► 1 1 . • i ,
. I M aJf -I. »
I « 1
» "i I
LEAN-SALINE LEAN-LOXI OBESE-SALINE OBESE-LOXI
Figure 1. Food intake of a carbohydrate rich meal (mean ± SEM) 
during saline or loxiglumide (LOXI) infusion (10 mg/kg ideal 
weight/h) by seven lean and seven obese healthy women.
Both lean and obese subjects liked bananas equally (59 ± 
9 and 65 ±  7 mm, respectively, on 100-mm visual analogue 
scales). The duration of the meal was significantly shorter 
with loxiglumide (5.1 ± 0.6 min) for obese subjects than 
during saline (7.3 ± 0.8 min,p <  .05), whereas lean subjects
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Figure 2. Food intake. Satiety parameters such as wish to eat, hunger, fullness, and prospective feeding intentions scored 
on visual analogue scales during loxiglumide (Loxi, 10 mg/kg ideal body weight/h) infusion from time 0 min to time 165 
min in 14 healthy women (seven lean women, seven obese women). Satiety scores are expressed in percentual changes 
considering the start of loxiglumide infusion time (0 min) as a reference point. At time 60 min, a banana shake (p = preload) 
was ingested; at time 75 min a carbohydrate-rich meal was consumed until satiation.
receptor antagonist was administered by continuous intra­
venous infusion. Previous studies have shown that the dose 
of loxiglumide we infused completely inhibits pancreatic 
enzyme secretion and gallbladder contraction in response to 
exogenous CCK (Schmidt et al 1991). Second, in the study 
of Wolkowitz et al, the subjects scored their first visual 
analogue scale as early as 5.45 h a m , ingested MK-329 
orally, and 90 min later scored their second visual analogue 
scale. In our study, which started at 8.00 h a m , the mean of 5 
visual analogue scales was used for the basal hunger score 
and hunger feelings were scored every 15 minutes during 
intravenous administration of the CCK-receptor antagonist 
loxiglumide. Sixty minutes after the start of the loxiglumide 
infusion, a banana shake was consumed. Third, Wolkowitz 
et al investigated male volunteers, whereas we investigated 
female subjects.
The results of our study are in agreement with those of 
Drewe et al (1992), who found no influence of loxiglumide 
on hunger feelings or food intake in lean, healthy subjects. 
That study, however, was performed with an intraduodenal 
tube in situ; it cannot be excluded that the duodenal intuba­
tion may have adversely affected the results. A more likely 
explanation for the fact that we did not observe a significant 
increase in food intake or in postprandial hunger feelings 
during loxiglumide administration may be related to the 
composition of the meal. In our study we offered a carbohy­
drate-rich meal that does not release endogenous CCK. It is 
well known that fat and protein, but not carbohydrates, are 
potent stimuli of CCK secretion. It therefore remains possi­
ble that blockade of CCK-A receptors increases food intake 
when a protein or fat meal, which induces CCK release, is 
consumed. In further studies evaluating the effect of CCK-
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importance because it was not associated with increases in 
hunger scores, wish to eat, or a decrease in feelings of 
fullness.
A remarkable finding of this study was the significantly receptor antagonist loxiglumide in lean and obese 
stronger postprandial satiety effect during loxiglumide in­
fusion in obese as compared to lean individuals. This differ­
ence in postprandial satiety was present for wish to eat, 
hunger, and fullness (each p  <  .01), and there was a trend
towards statistical significance for prospective feeding in- t0 Mrs- M- Biewinga-Kok, Mrs. M. Koster-de Vreese, and Ms. J.W. van
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